Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04657822 · ClinicalTrials.gov registry record · Phase 4

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

A Phase 4 study of Sickle Cell Disease, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
Phase 4
Development phase
130
Enrollment target
20
Study locations

NCT04657822 is a Phase 4 study of Sickle Cell Disease that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 130 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04657822, a Phase 4 study of Sickle Cell Disease, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
Phase 4
Development phase
130 participants
Enrollment target
20
Study locations

Study Summary

This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.

Conditions Studied

Sickle Cell Disease

Interventions

  • DRUG Crizanlizumab

Study Locations (20)

Other

  • Novartis Investigative Site - Brussels
  • Novartis Investigative Site - Laken
  • Novartis Investigative Site - Liège
  • Novartis Investigative Site - Montería
  • Novartis Investigative Site - Créteil
  • Novartis Investigative Site - Paris
  • Novartis Investigative Site - Paris
  • Novartis Investigative Site - Heidelberg

North Carolina

  • East Carolina University - Greenville
  • East Carolina University - Greenville

São Paulo

  • Novartis Investigative Site - Ribeirão Preto
  • Novartis Investigative Site - São Paulo

Alabama

  • University Of Alabama - Birmingham

District of Columbia

  • Childrens National Hospital - Washington D.C.

Georgia

  • Augusta University Georgia - Augusta

Pennsylvania

  • Childrens Hospital of Philadelphia - Philadelphia

Texas

  • Cook Childrens Medical Center - Fort Worth

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2021-06-10
Est. Completion 2031-06-10
Phase Phase 4

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04657822

The ClinicalTrials.gov registry entry for NCT04657822 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (55% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Crizanlizumab is the first listed.

NCT04657822 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, North Carolina, São Paulo.

Frequently Asked Questions

What is clinical trial NCT04657822 about?

NCT04657822 is a clinical study titled "Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study". This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.

What is the current status of trial NCT04657822?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 130 participants. The study started on 2021-06-10. Estimated completion is 2031-06-10.

What conditions does trial NCT04657822 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

What interventions are being tested in trial NCT04657822?

The interventions under investigation include: Crizanlizumab (DRUG).

Who is sponsoring clinical trial NCT04657822?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04657822 being conducted?

This trial has 20 study locations across Alabama, District of Columbia, Georgia, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sickle Cell Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.